Cargando...
Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases
Brain metastases (BMs) are the most common cause of malignant central nervous system (CNS) tumors in adults. In the recent past, patients with BMs were excluded from clinical trials, but now, with the advent of new biological and immunological drugs, their inclusion is more common. In the last era r...
Gardado en:
| Publicado en: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
AME Publishing Company
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5233872/ https://ncbi.nlm.nih.gov/pubmed/28149758 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2016.11.02 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|